Last reviewed · How we verify
Pacritinib and Clarithromycin
At a glance
| Generic name | Pacritinib and Clarithromycin |
|---|---|
| Also known as | Pacritinib 100mg and Clarithromycin 500mg |
| Sponsor | CTI BioPharma |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- To Evaluate the Effect of Clarithromycin on the Systemic Exposure of Pacritinib in Healthy Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Pacritinib and Clarithromycin CI brief — competitive landscape report
- Pacritinib and Clarithromycin updates RSS · CI watch RSS
- CTI BioPharma portfolio CI